Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Schedule of Change in Accounts Receivable, Contract Assets and Liabilities (Details)

v3.21.2
Collaboration and Research Arrangements - Schedule of Change in Accounts Receivable, Contract Assets and Liabilities (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2021
USD ($)
Disaggregation Of Revenue [Line Items]  
Accounts receivable and contract assets, Balance at Beginning of Period $ 2,331
Accounts receivable and contract assets, Additions 15,701
Accounts receivable and contract assets, Deductions (14,400)
Accounts receivable and contract assets, Balance at End of Period 3,632
Contract liabilities, Balance at Beginning of Period 22,086
Contract liabilities, Additions 145
Contract liabilities, Deduction (7,256)
Contract liabilities, Balance at End of Period 14,975
Incyte  
Disaggregation Of Revenue [Line Items]  
Contract liabilities, Balance at Beginning of Period 5,365
Contract liabilities, Deduction (2,766)
Contract liabilities, Balance at End of Period 2,599
Global Blood Therapeutics  
Disaggregation Of Revenue [Line Items]  
Contract liabilities, Balance at Beginning of Period 16,721
Contract liabilities, Additions 145
Contract liabilities, Deduction (4,490)
Contract liabilities, Balance at End of Period 12,376
Billed receivables from collaboration partners  
Disaggregation Of Revenue [Line Items]  
Accounts receivable, Balance at Beginning of Period 7
Accounts receivable, Additions 7,270
Accounts receivable, Deduction (7,277)
Unbilled receivables from collaboration partners  
Disaggregation Of Revenue [Line Items]  
Contract assets, Balance at Beginning of Period 2,324
Contract assets, Additions 8,431
Contract assets, Deduction (7,123)
Contract assets, Balance at End of Period $ 3,632